• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

MultiVu Video Feed: FDA Approves Two New Indications for Rituxan(R) (RITUXIMAB) in Patients With Non-Hodgkin's Lymphoma

Posted on: Friday, 29 September 2006, 21:00 CDT

NEW YORK, Sept. 29 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved two additional uses for Rituxan for patients with CD20- positive, B-cell non-Hodgkin's lymphoma (NHL).

* One new indication for Rituxan is for first-line treatment of previously untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. * The second new indication is for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy.

NHL is the sixth most fatal cancer in the U.S. and an estimated 360,000 Americans have NHL -- more than 58,000 new cases are diagnosed annually. About 30 percent of those patients diagnosed have a slow-growing, but incurable (low-grade) form of the disease -- the most common type is called follicular lymphoma. Relapse is common in these patients, making the goal of treatment to delay disease progression for as long as possible.

The second new Rituxan indication represents a new approach to the treatment of NHL, enabling doctors to treat patients front-line with Rituxan, already one of the standard therapies for NHL, on an extended basis following a good response to upfront CVP chemotherapy. Studies showed that this treatment approach helped reduce the risk of disease progression, relapse or death in certain NHL patients.

SATELLITE FEEDS: Friday, September 29th, 2006 Saturday, September 30th, 2006 8:00 PM - 8:15 PM ET 10:30 AM - 10:45 AM ET IA 6 IA 6 Transponder 15 Transponder 15 C-Band C-Band Downlink: 4000 Vertical Downlink: 4000 Vertical Monday, October 2nd, 2006 3:30 AM - 3:45 AM ET Transponder 15 C-Band Downlink: 4000 Vertical Preview and access this video on Pathfire DMG: 25461 Search within the PR Newswire or MultiVu section by story ID # 25461 or by headline For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com NEWS: FDA Approves Expanded Uses of Rituxan for Non-Hodgkin's Lymphoma FORMAT: B-Roll with Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at http://www.prnewswire.com/broadcast/25461/consumer.shtml

SOUNDBITES: * Howard Hochster, M.D., New York University Cancer Institute * Merril Hoge, Patient With Follicular Non-Hodgkin's Lymphoma, ESPN Analyst And Former Pittsburgh Steeler

B-ROLL INCLUDES: ***Doctor/Patient Footage***Rituxan Administration Footage***Manufacturing Footage***

VIDEO PROVIDED BY: Genentech and Biogen Idec

Video: http://www.prnewswire.com/broadcast/25461/press.shtml

Genentech and Biogen Idec

CONTACT: FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE CALL:MultiVu Media Relations, +1-800-653-5313, ext. 3

Web site: http://www.multivu.com/

Source: PRNewswire

More News in this Category